ARVINAS, INC. — Director's Dealing 2018

Sep 26, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ARVINAS HOLDING COMPANY, LLC (ARVN)
CIK: 0001655759
Period of Report: 2018-09-26

Reporting Person: RA CAPITAL MANAGEMENT, LLC (10% Owner)
Reporting Person: Kolchinsky Peter (10% Owner)
Reporting Person: RA Capital Healthcare Fund LP (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series B Preferred Stock	$		Common Stock (1847002)		Indirect
Series C Preferred Stock	$		Common Stock (291410)		Indirect

Footnotes

F1: Upon the closing of the Issuer's initial public offering, each 3.25 shares of preferred stock will convert into one share of common stock. The preferred stock has no expiration date.

F2: RA Capital Management, LLC (the "Adviser") is the general partner of RA Capital Healthcare Fund, L.P. (the "Fund") and the investment adviser for a separately managed account (the "Account"). Peter Kolchinsky is the sole manager of the Adviser. In their respective capacities, each of the Adviser and Dr. Kolchinsky may be deemed to beneficially own the reported securities for purposes of Section 13(d) of the Securities Exchange Act of 1934.

F3: The Adviser and Mr. Kolchinsky disclaim beneficial ownership of the reported securities for purposes of Rule 16a-1(a)(1) under the Exchange Act in reliance on Rule 16a-1(a)(1)(v) and (vii), respectively, and therefore disclaim any obligation to report ownership of the reported securities under Section 16(a) of the Exchange Act. The filing of this Form 3 shall not be construed as an admission that either the Adviser or Mr. Kolchinsky is or was, for purposes of Rule 16a-1(a)(1) under the Exchange Act, the beneficial owner of any of the securities reported herein. Mr. Kolchinsky and the Adviser disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a)(2) under the Exchange Act except to the extent of their pecuniary interest therein.

F4: Includes 1,551,482 shares of the Issuer's common stock issuable upon conversion of Series B Preferred Stock held by the Fund and 295,520 shares of the Issuer's common stock issuable upon conversion of Series B Preferred Stock held by the Account.

F5: Includes 237,208 shares of the Issuer's common stock issuable upon conversion of Series C Preferred Stock held by the Fund and 54,202 shares of the Issuer's common stock issuable upon conversion of Series C Preferred Stock held by the Account.